These emerging treatments, Semaglutide , represent a groundbreaking advancement in treating type 2 diabetes and potentially other ailments . They are grouped as GLP-1 hormone agonists , meaning they function to mimic the body's GLP-1 hormone , boosting glucose release and suppressing food intake.